Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Phase 3

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Sponsor:

ML Bio Solutions, Inc.

Code:

NCT05775848

Conditions

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Eligibility Criteria

Sex: All

Age: 12 - 60

Healthy Volunteers: Not accepted

Interventions

BBP-418 (ribitol)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information